A practical reference on GRF(1-29): what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-30 and is reviewed periodically as new material appears.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
=== Detection in body fluids === Blood, serum, or plasma topiramate concentrations may be measured using immunoassay or chromatographic methods to monitor therapy, confirm a diagnosis of poisoning in hospitalized patients, or assist in a medicolegal death investigation. Plasma levels are usually less than 10 mg/L during therapeutic administration, but can range from 10 to 150 mg/L in overdose victims.
The substances were more effective than placebo in the two studies included but the authors state that "the evidence was of insufficient quality to be conclusive" and note that "because alternative antidepressants exist which have been proven to be effective and safe, the clinical usefulness of 5-HTP and tryptophan is limited at present". The use of tryptophan as an adjunctive therapy in addition to standard treatment for mood and anxiety disorders is not supported by the scientific evidence.
== Refinements == Archimedes' principle does not consider the surface tension (capillarity) acting on the body. Moreover, Archimedes' principle has been found to break down in complex fluids. There is an exception to Archimedes' principle known as the bottom (or side) case. This occurs when a side of the object is touching the bottom (or side) of the vessel it is submerged in, and no liquid seeps in along that side. In this case, the net force has been found to be different from Archimedes' principle, as, since no fluid seeps in on that side, the symmetry of pressure is broken.
=== 2016: Federal Supreme Court appeal === Following the CAS finding, the sole remaining avenue for appeal was the Federal Supreme Court of Switzerland, under whose jurisdiction the CAS sits. An appeal was lodged on 10 February, arguing that the CAS did not have legal grounds to conduct a de novo hearing and could have appealed the AFL Tribunal's verdict only based on legal error or gross unreasonableness. During the year, both parties submitted paperwork in German to the Federal Supreme Court. The court deliberated on the written submissions, and on 11 October 2016 dismissed the appeal, upholding the guilty verdicts and the suspensions:
== Formulation == Dakin's original solution contained sodium hypochlorite (0.4% to 0.5%), prepared by treating calcium hypochlorite with sodium carbonate ("washing soda"). The solution left after removal of the insoluble calcium carbonate still contained some soda. Boric acid (4%) was then added as a buffering agent to maintain a pH of between 9 and 10. Dakin found that alkalinity outside this range was too irritating. The solution, while unstable, remains effective for at least a week, if made to the correct pH. Other formulations have been developed over time. In 1916, Marcel Daufresne substituted sodium bicarbonate for Dakin's boric acid as buffering agent. This formulation is the basis of current commercial products. The concentration chosen by Dakin (0.5%) was the maximum highest concentration found tolerable to the skin. It is the concentration recommended by the U.S. Centers for Disease Control (CDC) as a household disinfectant. In one study, bactericidal effects of sodium hypochlorite solution were observed at concentrations as low as 0.025%, without any tissue toxicity in vivo or in vitro. It recommended that concentration be adopted as a "modified Dakin's solution" for wound dressing. Currently, various concentrations are sold for wound cleansing including Anasept (0.057%), 1/4 strength Dakin's (0.125%), and Di-Dak-Sol or Dakin's Wound Cleanser (0.0125%) which is 1/40 strength.
Sources: en.wikipedia.org
Austin was involved in the concluding segment at ECW One Night Stand on June 12 in which he had a beer bash with the ECW locker room. He also appeared on the internet themed event Cyber Sunday in 2007 and 2008. Austin also made appearenced to promote WWE material, like the WWE Films' production The Condemned, the revival of Tough Enough in 2011.
Diethyltryptamine (DET), also known as N,N-diethyltryptamine or T-9, is a psychedelic drug of the tryptamine family closely related to dimethyltryptamine (DMT). It is taken orally, but can also be used by parenteral routes. The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor among others. It has not been found to occur endogenously. DET is a close structural homologue of DMT and dipropyltryptamine (DPT). Other analogues of DET include 4-HO-DET (ethocin), ethocybin (4-PO-DET), and 5-MeO-DET. DET was first synthesized in 1956 by Stephen Szára and subsequently described in material published in 1957. More systematic studies were reported later by Szára and colleagues and independently by Böszörményi and colleagues.
As part of the angiogenic signaling cascade, NO is widely considered to be a major contributor to the angiogenic response because inhibition of NO significantly reduces the effects of angiogenic growth factors. However, inhibition of NO during exercise does not inhibit angiogenesis, indicating there are other factors involved in the angiogenic response.
==== Refrigeration ==== Food storage in refrigerators may not be safe unless there is close adherence to temperature guidelines. In general, the temperature should be maintained at 4 °C (39 °F) or below, but never below 1 °C (34 °F). Safe storage times vary by food and may depend on how the food was handled before being placed in the refrigerator.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.